Ocugen, Inc. (NASDAQ:OCGN) is shattering all records and is currently up over 200%. More than 368M shares have exchanged hands with stock prices climbing as high as 15.90$. Earlier today, Ocugen Inc. announced $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market.
Wall Street is all drooling over Ocugen’s recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Could OCGN be a AMC or GME in the making ? Its tough to predict considering that stocks are all moving on social media sentiments and chatter. Its important to follow traders vigilance. OCGN may soon issue a statement considering the recent price action.
Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering.